Gufic Biosciences is currently trading at Rs. 237.45, up by 4.90 points or 2.11% from its previous closing of Rs. 232.55 on the BSE.
The scrip opened at Rs. 239.55 and has touched a high and low of Rs. 245.00 and Rs. 235.85 respectively. So far 25968 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 245.00 on 19-Sep-2022 and a 52 week low of Rs. 177.10 on 29-Mar-2023.
Last one week high and low of the scrip stood at Rs. 245.00 and Rs. 195.25 respectively. The current market cap of the company is Rs. 2254.44 crore.
The promoters holding in the company stood at 75.00%, while Institutions and Non-Institutions held 1.88% and 23.12% respectively.
Gufic Biosciences (Gufic) has received approval from National Medical Products Administration (NMPA), China for its product PRILOCAINE (API) which is an amide-type local anaesthetic of fast onset and intermediate duration of action. This approval shall help commercialization of the said product in China and explore Chinese market.
Gufic Biosciences is engaged in diversified business viz. Pharma, Healthcare, Bio- Technology, Seeds, Herbal etc.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1830.20 |
Dr. Reddys Lab | 1183.00 |
Cipla | 1549.65 |
Lupin | 2094.65 |
Zydus Lifesciences | 887.70 |
View more.. |